Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial
10.1016/j.ygyno.2017.02.039
Saved in:
Main Authors: | Wysham, Weiya Z, Schaffer, Elisabeth M, Coles, Theresa, Roque, Dario R, Wheeler, Stephanie B, Kim, Kenneth H |
---|---|
Other Authors: | DUKE-NUS MEDICAL SCHOOL |
Format: | Article |
Published: |
Elsevier BV
2023
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/239625 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4
by: Kim, YN, et al.
Published: (2023) -
Bevacizumab promotes T-cell–mediated collagen deposition in the mouse model of conjunctival scarring
by: Seet, Li-Fong, et al.
Published: (2019) -
Bevacizumab Promotes T-Cell-Mediated Collagen Deposition in the Mouse Model of Conjunctival Scarring
by: Seet L.-F., et al.
Published: (2019) -
Effective inhibition of xenografts of hepatocellular carcinoma (hepg2) by rapamycin and bevacizumab in an intrahepatic model
by: Ong, L.-C., et al.
Published: (2014) -
Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer
by: Yadav, Kritika, et al.
Published: (2023)